| Level/ Typ |
Code |
Anzeigename |
Codesystem |
| 0‑L |
A
|
Alimentäres System und Stoffwechsel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01
|
Stomatologika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01a
|
Stomatologika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA
|
Mittel zur Kariesprophylaxe
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA01
|
Natriumfluorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA02
|
Natriummonofluorphosphat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA03
|
Olaflur
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA04
|
Zinn(II)-fluorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AA51
|
Natriumfluorid, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB
|
Antiinfektiva und Antiseptika zur oralen Lokalbehandlung
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB02
|
Wasserstoffperoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB03
|
Chlorhexidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB04
|
Amphotericin B
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB05
|
Polynoxylin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB06
|
Domiphen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB07
|
Oxychinolin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB08
|
Neomycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB09
|
Miconazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB10
|
Natamycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB11
|
Verschiedene
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB12
|
Hexetidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB13
|
Tetracyclin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB14
|
Benzoxoniumchlorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB15
|
Tibezoniumiodid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB16
|
Mepartricin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB17
|
Metronidazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB18
|
Clotrimazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB19
|
Natriumperborat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB21
|
Chlortetracyclin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB22
|
Doxycyclin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AB23
|
Minocyclin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AC
|
Corticosteroide zur oralen Lokalbehandlung
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AC01
|
Triamcinolon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AC02
|
Dexamethason
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AC03
|
Hydrocortison
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AC54
|
Prednisolon, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD
|
Andere Mittel zur oralen Lokalbehandlung
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD01
|
Epinephrin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD02
|
Benzydamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD05
|
Acetylsalicylsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD06
|
Adrenalon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD07
|
Amlexanox
|
2.16.840.1.113883.6.73 |
| 0‑L |
A01AD11
|
Verschiedene
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02
|
Mittel bei säure bedingten Erkrankungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02A
|
Antacida
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA
|
Magnesium-haltige Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA01
|
Magnesiumcarbonat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA02
|
Magnesiumoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA03
|
Magnesiumperoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA04
|
Magnesiumhydroxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA05
|
Magnesiumsilikat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AA10
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB
|
Aluminium-haltige Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB01
|
Aluminiumhydroxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB02
|
Algeldrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB03
|
Aluminiumphosphat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB04
|
Dihydroxyalumiumnatriumcarbonat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB05
|
Aluminiumacetoacetat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB06
|
Aloglutamol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB07
|
Aluminiumglycinat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AB10
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AC
|
Calcium-haltige Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AC01
|
Calciumcarbonat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AC02
|
Calciumsilikat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AC10
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD
|
Kombinationen und Komplexe von Aluminium-, Calcium- und Magnesium-haltigen Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD01
|
Einfache Salzkombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD02
|
Magaldrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD03
|
Almagat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD04
|
Hydrotalcit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AD05
|
Almasilat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AF
|
Antacida mit Karminativa
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AF01
|
Magaldrat und Karminativa
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AF02
|
Einfache Salzkombinationen und Karminativa
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AG
|
Antacida mit Spasmolytika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AH
|
Antacida mit Natriumbicarbonat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02AX
|
Antacida, andere Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02B
|
Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA
|
Histamin-H2-Rezeptorantagonisten
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA01
|
Cimetidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA02
|
Ranitidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA03
|
Famotidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA04
|
Nizatidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA05
|
Niperotidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA06
|
Roxatidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA07
|
Ranitidinbismutcitrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA08
|
Lafutidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA51
|
Cimetidin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BA53
|
Famotidin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BB
|
Prostaglandine
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BB01
|
Misoprostol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BB02
|
Enprostil
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC
|
Protonenpumpenhemmer
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC01
|
Omeprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC02
|
Pantoprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC03
|
Lansoprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC04
|
Rabeprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC05
|
Esomeprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BC06
|
Dexlansoprazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD
|
Kombinationen zur Eradikation von Helicobacter pylori
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD01
|
Omeprazol, Amoxicillin und Metronidazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD02
|
Lansoprazol, Tetracyclin und Metronidazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD03
|
Lansoprazol, Amoxicillin und Metronidazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD04
|
Pantoprazol, Amoxicillin und Clarithromycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD05
|
Omeprazol, Amoxicillin und Clarithromycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD06
|
Esomeprazol, Amoxicillin und Clarithromycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BD08
|
Bismutsubcitrat, Tetracyclin und Metronidazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX
|
Andere Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX01
|
Carbenoxolon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX02
|
Sucralfat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX03
|
Pirenzepin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX04
|
Methiosulfoniumchlorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX05
|
Bismutsubcitrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX06
|
Proglumid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX07
|
Gefarnat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX08
|
Sulglicotid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX09
|
Acetoxolon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX10
|
Zolimidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX11
|
Troxipid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX12
|
Bismutsubnitrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX13
|
Alginsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX51
|
Carbenoxolon, Kombinationen exkl. Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX71
|
Carbenoxolon, Kombinationen mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02BX77
|
Gefarnat, Kombinationen mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A02X
|
Andere Mittel bei säure bedingten Erkrankungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03
|
Mittel bei funktionellen gastrointestinalen Störungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03A
|
Mittel bei funktionellen Störungen des Darms
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA
|
Synthetische Anticholinergika, Ester mit tertiären Aminogruppen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA01
|
Oxyphencyclimin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA03
|
Camylofin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA04
|
Mebeverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA05
|
Trimebutin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA06
|
Rociverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA07
|
Dicycloverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA08
|
Dihexyverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA09
|
Difemerin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AA30
|
Piperidolat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB
|
Synthetische Anticholinergika, quartäre Ammonium-Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB01
|
Benzilon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB02
|
Glycopyrronium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB03
|
Oxyphenonium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB04
|
Penthienat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB05
|
Propanthelin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB06
|
Otiloniumbromid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB07
|
Methanthelinium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB08
|
Tridihexethyl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB09
|
Isopropamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB10
|
Hexocyclium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB11
|
Poldin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB12
|
Mepenzolat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB13
|
Bevonium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB14
|
Pipenzolat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB15
|
Diphemanil
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB16
|
(2-Benzhydryloxyethyl)diethylmethyl-ammoniumiodid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB17
|
Tiemoniumiodid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB18
|
Prifiniumbromid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB19
|
Timepidiumbromid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB21
|
Fenpiverinium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AB53
|
Oxyphenonium, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AC
|
Synthetische Spasmolytika, Amide mit tertiären Aminen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AC02
|
Dimethylaminopropionylphenothiazin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AC04
|
Nicofetamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AC05
|
Tiropramid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AD
|
Papaverin und Derivate
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AD01
|
Papaverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AD02
|
Drotaverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AD30
|
Moxaverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AE
|
Auf Serotonin-Rezeptoren wirkende Mittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AE01
|
Alosetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AE02
|
Tegaserod
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AE03
|
Cilansetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX
|
Andere Mittel bei funktionellen Störungen des Darms
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX01
|
Fenpipran
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX02
|
Diisopromin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX03
|
Chlorbenzoxamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX04
|
Pinaverium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX05
|
Fenoverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX06
|
Idanpramin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX07
|
Proxazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX08
|
Alverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX09
|
Trepibuton
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX10
|
Isomethepten
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX11
|
Caroverin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX12
|
Phloroglucinol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX13
|
Silikone
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX30
|
Trimethyldiphenylpropylamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03AX58
|
Alverin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03B
|
BELLADONNA UND DERIVATE, REIN
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BA
|
Belladonna-Alkaloide, tertiäre Amine
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BA01
|
Atropin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BA03
|
Hyoscyamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BA04
|
Belladonna-Gesamtalkaloide
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB
|
Belladonna-Alkaloide, halbsynthetisch, quartäre Ammonium-Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB01
|
Butylscopolamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB02
|
Methylatropin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB03
|
Methylscopolamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB04
|
Fentonium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03BB05
|
Cimetropiumbromid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03C
|
Spasmolytika in Kombination mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA
|
Synthetische Anticholinergika in Kombination mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA01
|
Isopropamid und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA02
|
Clidinium und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA03
|
Oxyphencyclimin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA04
|
Otiloniumbromid und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA05
|
Glycopyrronium und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA06
|
Bevonium und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA07
|
Ambutonium und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA08
|
Diphemanil und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA30
|
Emepronium und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CA34
|
Propanthelin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB
|
Belladonna und Derivate in Kombination mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB01
|
Methylscopolamin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB02
|
Belladonna-Gesamtalkaloide und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB03
|
Atropin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB04
|
Methylhomatropin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CB31
|
Hyoscyamin und Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03CC
|
Andere Spasmolytika in Kombination mit Psycholeptika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03D
|
Spasmolytika in Kombination mit Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA
|
Synthetische Anticholinergika in Kombination mit Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA01
|
Tropenzilon und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA02
|
Pitofenon und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA03
|
Bevonium und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA04
|
Ciclonium und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA05
|
Camylofin und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA06
|
Trospium und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DA07
|
Tiemoniumiodid und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DB
|
Belladonna und Derivate in Kombination mit Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DB04
|
Butylscopolamin und Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03DC
|
Andere Spasmolytika in Kombination mit Analgetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03E
|
Spasmolytika und Anticholinergika in Kombination mit anderen Mitteln
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03EA
|
Spasmolytika, Psycholeptika und Analgetika in Kombination
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03ED
|
Spasmolytika in Kombination mit anderen Mitteln
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03F
|
Prokinetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA
|
Prokinetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA01
|
Metoclopramid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA02
|
Cisaprid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA03
|
Domperidon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA04
|
Bromoprid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA05
|
Alizaprid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A03FA06
|
Cleboprid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04
|
Antiemetika und Mittel gegen Übelkeit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04A
|
Antiemetika und Mittel gegen Übelkeit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA
|
Serotonin-5HT3-Antagonisten
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA01
|
Ondansetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA02
|
Granisetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA03
|
Tropisetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA04
|
Dolasetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AA05
|
Palonosetron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD
|
Andere Antiemetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD01
|
Scopolamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD02
|
Ceriumoxalat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD04
|
Chlorbutanol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD05
|
Metopimazin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD10
|
Dronabinol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD11
|
Nabilon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD12
|
Aprepitant
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD51
|
Scopolamin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A04AD54
|
Chlorbutanol, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05
|
Gallen- und Lebertherapie
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05A
|
Gallentherapie
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AA
|
Gallensäure-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AA01
|
Chenodeoxycholsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AA02
|
Ursodeoxycholsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AB
|
Zubereitungen zur Gallentherapie
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AB01
|
N-(Hydroxymethyl)nicotinamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AX
|
Andere Mittel zur Gallentherapie
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AX01
|
Piprozolin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AX02
|
Hymecromon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05AX03
|
Cyclobutyrol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05B
|
Lebertherapie, Lipotrope Substanzen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA
|
Lebertherapie
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA01
|
Argininglutamat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA03
|
Silymarin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA04
|
Citiolon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA05
|
Epomediol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA06
|
Ornithinoxoglurat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05BA07
|
Tidiacicarginin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A05C
|
Mittel zur Gallentherapie und Lipotrope Substanzen in Kombination
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06
|
Laxanzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06A
|
Laxanzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AA
|
Gleitmittel, Emollientia
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AA01
|
Dickflüssiges Paraffin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AA02
|
Docusat-Natrium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AA51
|
Dickflüssiges Paraffin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB
|
Kontaktlaxanzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB01
|
Oxyphenisatin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB02
|
Bisacodyl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB03
|
Dantron
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB04
|
Phenolphthalein
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB05
|
Rizinusöl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB06
|
Sennoside
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB07
|
Cascara
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB08
|
Natriumpicosulfat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB09
|
Bisoxatin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB20
|
Kontaktlaxanzien in Kombination
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB30
|
Kontaktlaxanzien in Kombination mit Belladonna-Alkaloiden
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB52
|
Bisacodyl, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB53
|
Dantron, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB56
|
Sennoside, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB57
|
Cascara, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AB58
|
Natriumpicosulfat, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC
|
Quellmittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC01
|
Ispaghula (Flohsamen)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC02
|
Ethulose
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC03
|
Sterculia
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC05
|
Leinsamen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC06
|
Methylcellulose
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC07
|
Triticum (Weizenkleie)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC08
|
Polycarbophil-Calcium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC51
|
Ispaghula, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC53
|
Sterculia, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AC55
|
Leinsamen, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD
|
Osmotisch wirkende Laxanzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD01
|
Magnesiumcarbonat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD02
|
Magnesiumoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD03
|
Magnesiumperoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD04
|
Magnesiumsulfat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD10
|
Mineralsalze in Kombination
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD11
|
Lactulose
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD12
|
Lactitol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD13
|
Natriumsulfat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD14
|
Pentaerythrityl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD15
|
Macrogol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD16
|
Mannitol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD17
|
Natriumphosphat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD18
|
Sorbitol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD19
|
Magnesiumcitrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD21
|
Natriumtartrat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD61
|
Lactulose, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AD65
|
Macrogol, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG
|
Klysmen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG01
|
Natriumphosphat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG02
|
Bisacodyl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG03
|
Dantron, inkl. Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG04
|
Glycerol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG06
|
Öl
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG07
|
Sorbitol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG10
|
Docusat-Natrium, inkl. Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG11
|
Laurylsulfat, inkl. Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AG20
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AH01
|
Methylnaltrexon bromid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AX
|
Andere Laxanzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AX01
|
Glycerol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A06AX02
|
Kohlendioxid-freisetzende Mittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07
|
Antidiarrhoika und intestinale Antiphlogistika/Antiinfektiva
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07A
|
Intestinale Antiinfektiva
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA
|
Antibiotika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA01
|
Neomycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA02
|
Nystatin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA03
|
Natamycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA04
|
Streptomycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA05
|
Polymyxin B
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA06
|
Paromomycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA07
|
Amphotericin B
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA08
|
Kanamycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA09
|
Vancomycin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA10
|
Colistin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA11
|
Rifaximin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA12
|
Fidaxomicin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA51
|
Neomycin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AA54
|
Streptomycin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AB
|
Sulfonamide
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AB02
|
Phthalylsulfathiazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AB03
|
Sulfaguanidin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AB04
|
Succinylsulfathiazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AC
|
Imidazol-Derivate
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AC01
|
Miconazol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AX
|
Andere intestinale Antiinfektiva
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AX01
|
Broxychinolin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AX02
|
Acetarsol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AX03
|
Nifuroxazid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07AX04
|
Nifurzid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07B
|
Intestinale Adsorbenzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BA
|
Kohle-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BA01
|
Medizinische Kohle
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BA51
|
Medizinische Kohle, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BB
|
Bismut-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC
|
Andere intestinale Adsorbenzien
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC01
|
Pektin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC02
|
Kaolin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC03
|
Crospovidon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC04
|
Attapulgit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC05
|
Diosmectit
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07BC54
|
Attapulgit, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07C
|
Elektrolyte mit Kohlenhydraten
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07CA
|
Elektrolyte zur oralen Rehydrierung
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07D
|
Motilitätshemmer
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA
|
Motilitätshemmer
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA01
|
Diphenoxylat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA02
|
Opium
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA03
|
Loperamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA04
|
Difenoxin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA05
|
Loperamidoxid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA52
|
Morphin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07DA53
|
Loperamid, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07E
|
Intestinale Antiphlogistika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA
|
Corticosteroide mit lokaler Wirkung
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA01
|
Prednisolon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA02
|
Hydrocortison
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA03
|
Prednison
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA04
|
Betamethason
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA05
|
Tixocortol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA06
|
Budesonid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EA07
|
Beclometason
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EB
|
Antiallergika, exkl. Corticosteroide
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EB01
|
Cromoglicinsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EC
|
Aminosalicylsäure und ähnliche Mittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EC01
|
Sulfasalazin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EC02
|
Mesalazin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EC03
|
Olsalazin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07EC04
|
Balsalazid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07F
|
Mikrobielle Antidiarrhoika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07FA
|
Mikrobielle Antidiarrhoika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07FA01
|
Milchsäurebildner
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07FA02
|
Saccharomyces boulardii
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07FA51
|
Milchsäurebildner, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07X
|
Andere Antidiarrhoika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA
|
Andere Antidiarrhoika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA01
|
Albumintannat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA02
|
Ceratonia
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA03
|
Calcium-haltige Verbindungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA04
|
Racecadotril
|
2.16.840.1.113883.6.73 |
| 0‑L |
A07XA51
|
Albumintannat, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08
|
Abmagerungsmittel, Exkl. Diätetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08A
|
Abmagerungsmittel, Exkl. Diätetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA
|
Zentral wirkende Abmagerungsmittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA01
|
Phentermin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA02
|
Fenfluramin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA03
|
Amfepramon
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA04
|
Dexfenfluramin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA05
|
Mazindol
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA06
|
Etilamfetamin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA07
|
Cathin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA08
|
Clobenzorex
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA09
|
Mefenorex
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA10
|
Sibutramin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AA56
|
Ephedrin, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AB
|
Peripher wirkende Abmagerungsmittel
|
2.16.840.1.113883.6.73 |
| 0‑L |
A08AB01
|
Orlistat
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09
|
Digestiva, Inkl. Enzyme
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09A
|
Digestiva, Inkl. Enzyme
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AA
|
Enzym-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AA01
|
Diastase
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AA02
|
Multienzyme (Lipase, Protease etc.)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AA03
|
Pepsin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AA04
|
Tilactase
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AB
|
Säure-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AB01
|
Glutaminsäurehydrochlorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AB02
|
Betainhydrochlorid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AB03
|
Salzsäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AB04
|
Zitronensäure
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AC
|
Enzym- und Säure-haltige Zubereitungen, Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AC01
|
Pepsin- und Säure-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A09AC02
|
Multienzyme und säure-haltige Zubereitungen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10
|
Antidiabetika
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10A
|
Insuline Und Analoga
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AA
|
Insulins
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB
|
Insuline und Analoga zur Injektion, schnell wirkend
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB01
|
Insulin (human)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB02
|
Insulin (Rind)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB03
|
Insulin (Schwein)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB04
|
Insulin lispro
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB05
|
Insulin aspart
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB06
|
Insulin glulisin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AB30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC
|
Insuline und Analoga zur Injektion, intermediär wirkend
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC01
|
Insulin (human)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC02
|
Insulin (Rind)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC03
|
Insulin (Schwein)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC04
|
Insulin lispro
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AC30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD
|
Insuline und Analoga zur Injektion, intermediär wirkend kombiniert mit schnell wirkend
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD01
|
Insulin (human)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD02
|
Insulin (Rind)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD03
|
Insulin (Schwein)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD04
|
Insulin lispro
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD05
|
Insulin aspart
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AD30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE
|
Insuline und Analoga zur Injektion, lang wirkend
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE01
|
Insulin (human)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE02
|
Insulin (Rind)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE03
|
Insulin (Schwein)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE04
|
Insulin glargin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE05
|
Insulin detemir
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AE30
|
Kombinationen
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AF
|
Insuline und Analoga zur Inhalation
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10AF01
|
Insulin (human)
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10B
|
Antidiabetika, Exkl. Insuline
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BA
|
Biguanide
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BA01
|
Phenformin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BA02
|
Metformin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BA03
|
Buformin
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BB
|
Sulfonylharnstoff-Derivate
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BB01
|
Glibenclamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BB02
|
Chlorpropamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BB03
|
Tolbutamid
|
2.16.840.1.113883.6.73 |
| 0‑L |
A10BB04
|
Glibornurid
|
2.16.840.1.113883.6.73 |
| Dieses Value Set beinhaltet 6063 Codes. Um die Publikationsgröße überschaubar zu halten,
wird nur eine Auswahl (500 Codes) des ganzen Sets von Codes gezeigt.
|
|
Value Set ELGA_whoATC 2013‑01‑10
Definitiv
